Celltrion Pharm, Inc. (068760.KQ)
KRW 48600.0
(0.41%)
KRW 48600.0
(0.41%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 21.26 Billion KRW | -18.09% |
| 2022 | 25.95 Billion KRW | -24.93% |
| 2021 | 34.57 Billion KRW | 65.13% |
| 2020 | 20.93 Billion KRW | 143.42% |
| 2019 | 8.6 Billion KRW | 191.62% |
| 2018 | -9.38 Billion KRW | -445.84% |
| 2017 | 2.71 Billion KRW | 112.86% |
| 2016 | -21.1 Billion KRW | -413.43% |
| 2015 | 6.73 Billion KRW | 114628.28% |
| 2014 | 5.86 Million KRW | 124.62% |
| 2013 | 2.61 Million KRW | -26.43% |
| 2012 | 3.55 Million KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.89 Billion KRW | 166.65% |
| 2024 Q2 | 5.59 Billion KRW | 195.7% |
| 2023 Q3 | 3.3 Billion KRW | -68.73% |
| 2023 Q4 | 709.08 Million KRW | -78.53% |
| 2023 FY | 21.26 Billion KRW | -18.09% |
| 2023 Q1 | 6.69 Billion KRW | 8.06% |
| 2023 Q2 | 10.56 Billion KRW | 57.85% |
| 2022 FY | 25.95 Billion KRW | -24.93% |
| 2022 Q4 | 6.19 Billion KRW | -22.13% |
| 2022 Q1 | 4.27 Billion KRW | -16.23% |
| 2022 Q3 | 7.95 Billion KRW | 5.4% |
| 2022 Q2 | 7.54 Billion KRW | 76.62% |
| 2021 Q3 | 8.92 Billion KRW | -32.54% |
| 2021 Q4 | 5.09 Billion KRW | -42.89% |
| 2021 Q2 | 13.23 Billion KRW | 81.0% |
| 2021 Q1 | 7.31 Billion KRW | 67563.89% |
| 2021 FY | 34.57 Billion KRW | 65.13% |
| 2020 Q3 | 4.01 Million KRW | 3.0% |
| 2020 FY | 20.93 Billion KRW | 143.42% |
| 2020 Q4 | 10.8 Million KRW | 169.51% |
| 2020 Q2 | 3.89 Million KRW | 74.82% |
| 2020 Q1 | 2.22 Million KRW | -47.87% |
| 2019 FY | 8.6 Billion KRW | 191.62% |
| 2019 Q3 | 2.04 Million KRW | 2.72% |
| 2019 Q1 | 284.31 Thousand KRW | 108.16% |
| 2019 Q4 | 4.27 Million KRW | 108.47% |
| 2019 Q2 | 1.99 Million KRW | 601.81% |
| 2018 Q2 | -2.54 Million KRW | -666.46% |
| 2018 FY | -9.38 Billion KRW | -445.84% |
| 2018 Q1 | 450 Thousand KRW | -96.3% |
| 2018 Q4 | -3.48 Million KRW | 8.38% |
| 2018 Q3 | -3.8 Million KRW | -49.24% |
| 2017 Q1 | -1.57 Million KRW | 93.41% |
| 2017 Q2 | 3.3 Million KRW | 309.85% |
| 2017 FY | 2.71 Billion KRW | 112.86% |
| 2017 Q4 | 12.16 Million KRW | 567.08% |
| 2017 Q3 | 1.82 Million KRW | -44.84% |
| 2016 Q3 | 1.23 Million KRW | 716.77% |
| 2016 FY | -21.1 Billion KRW | -413.43% |
| 2016 Q1 | 1.4 Million KRW | 108.05% |
| 2016 Q2 | 151.18 Thousand KRW | -89.25% |
| 2016 Q4 | -23.89 Million KRW | -2035.3% |
| 2015 Q3 | 854 Thousand KRW | 245.23% |
| 2015 Q2 | 247.37 Thousand KRW | -78.45% |
| 2015 Q1 | 1.14 Million KRW | -33.18% |
| 2015 FY | 6.73 Billion KRW | 114628.28% |
| 2015 Q4 | -17.45 Million KRW | -2144.02% |
| 2014 Q3 | 1.15 Million KRW | -54.84% |
| 2014 FY | 5.86 Million KRW | 124.62% |
| 2014 Q4 | 1.71 Million KRW | 48.82% |
| 2014 Q2 | 2.55 Million KRW | 478.46% |
| 2014 Q1 | 441.83 Thousand KRW | 258.57% |
| 2013 Q3 | 1.63 Million KRW | 1624.45% |
| 2013 FY | 2.61 Million KRW | -26.43% |
| 2013 Q1 | 1.15 Million KRW | 38.14% |
| 2013 Q4 | -278.63 Thousand KRW | -116.99% |
| 2013 Q2 | 95.08 Thousand KRW | -91.78% |
| 2012 Q4 | 837.43 Thousand KRW | 0.0% |
| 2012 FY | 3.55 Million KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -19.42 Billion KRW | 209.458% |
| CMG Pharmaceutical Co., Ltd. | 6.45 Billion KRW | -229.417% |
| Huons Global Co., Ltd. | 38.38 Billion KRW | 44.599% |
| DongKook Pharmaceutical Co., Ltd. | 47.17 Billion KRW | 54.923% |
| Enzychem Lifesciences Corporation | -9.32 Billion KRW | 328.008% |
| Humedix Co., Ltd. | 24.82 Billion KRW | 14.326% |
| Boditech Med Inc. | 25.94 Billion KRW | 18.043% |
| EuBiologics Co., Ltd. | -13.87 Billion KRW | 253.217% |
| FutureChem Co.,Ltd | -6.7 Billion KRW | 416.965% |
| Huons Co., Ltd. | 50.47 Billion KRW | 57.869% |
| BNC Korea Co., Ltd. | 25.68 Billion KRW | 17.212% |
| AptaBio Therapeutics Inc. | -12.06 Billion KRW | 276.303% |